Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 7/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026402 | 0.92 | CACNA1F (0.56) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL11819347 | 0.89 | CACNA1F (0.72) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7266695 | 0.86 | CACNA1F (0.49) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7275780 | 0.85 | CACNA1F (0.67) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL9503033 | 0.85 | CACNA1F (0.80) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL10861491 | 0.85 | CACNA1F (0.67) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL6137184 | 0.85 | CACNA1C (0.64) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7586726 | 0.83 | CACNA1C (0.60) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL11777820 | 0.82 | CACNA1F (0.64) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL11780843 | 0.81 | CACNA1F (0.63) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165240-A1 | Method of treating proliferative diseases using Eg5 inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165240-A1 | Method of treating proliferative diseases using Eg5 inhibitors | ARF5, PDS5A, GEMIN5 | CACNA1C 4688/4885CACNA1F 4703/4885CACNA1D 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.